gemtuzumab ozogamicin

Home
Ligands
gemtuzumab ozogamicin

GtoPdb Ligand ID: 6775

Synonyms: CDP 771 | CMA 676 | hP67.6-calicheamicin | Mylotarg® | WAY-CMA 676

gemtuzumab ozogamicin is an approved drug (FDA (2000), EMA (2018))

Comment: This drug is an antibody-drug conjugate (ADC) that targets delivery of the highly cytotoxic ozogamicin (a derivative of calicheamicin γ1) to CD33 +ve myeloid cells [1].

Summary
Biological activity
Clinical data
References
Immunopharmacology

Immunopharmacology Comments
Gemtuzumab ozogamicin is an immune checkpoint modulator that delivers a toxic payload to target cancer cells.

Immunopharmacology Comments

Gemtuzumab ozogamicin is an immune checkpoint modulator that delivers a toxic payload to target cancer cells.

Immunopharmacology Disease
Disease	X-Refs	Comment	References
Acute myeloid leukemia	Disease Ontology: DOID:9119 OMIM: 601626 Orphanet: ORPHA519	Approved in particular for CD33-positive AML. However, note that use in this indication has been withdrawn in some jurisdictions due to safety concerns and lack of significant efficacy.